CA2312744C - Apparatus and method for diluting nasal sprays containing addictive compounds - Google Patents
Apparatus and method for diluting nasal sprays containing addictive compounds Download PDFInfo
- Publication number
- CA2312744C CA2312744C CA002312744A CA2312744A CA2312744C CA 2312744 C CA2312744 C CA 2312744C CA 002312744 A CA002312744 A CA 002312744A CA 2312744 A CA2312744 A CA 2312744A CA 2312744 C CA2312744 C CA 2312744C
- Authority
- CA
- Canada
- Prior art keywords
- spray
- diluent
- indicia
- container
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007922 nasal spray Substances 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 30
- 150000001875 compounds Chemical class 0.000 title claims abstract description 14
- 238000007865 diluting Methods 0.000 title claims abstract description 8
- 229940097496 nasal spray Drugs 0.000 claims abstract description 31
- 239000007921 spray Substances 0.000 claims abstract description 29
- 239000003085 diluting agent Substances 0.000 claims abstract description 26
- 230000000779 depleting effect Effects 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229960001528 oxymetazoline Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012895 dilution Substances 0.000 abstract description 3
- 238000010790 dilution Methods 0.000 abstract description 3
- 206010012335 Dependence Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002650 habitual effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000133 nasal decongestant Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960000833 xylometazoline Drugs 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229940064713 other nasal preparations in atc Drugs 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
Abstract
An apparatus and method capable of diluting nasal sprays containing addictive compounds. The user can safely and gradually withdraw from use of nasal sprays with successive dilutions using the apparatus having at least one indicia and a pre-selected level on the container. The spray is administered by the user using the method by depleting the nasal spray to the pre-selected level and replenishing with a diluent. The method steps are repeated until the concentration of the nasal spray is substantially reduced.
Description
APPARATUS AND METHOD FOR DILUTING NASAL SPRAYS
CONTAINING ADDICTIVE COMPOUNDS
This invention relates to an apparatus and method for diluting nasal sprays containing addictive compounds which substantially reduces the strength of the spray.
Millions of people suffer from the symptoms of the common cold or other sinus-related problems, such as sinusitis and hay fever. Included among these symptoms is "rhinitis," a 0 medical term for blocked or clogged sinuses. Seeking relief from these symptoms, symptomatic persons use nasal decongestants which are available over-the-counter without a prescription. The most popular of these decongestants contain oxymetazoline or a pharmaceutically acceptable salt thereof. Other nasal preparations available over-the-counter contain compounds such as xylometazoline, naphazoline, phenylephrine and pharmaceutically acceptable salts thereof.
Nasal decongestants containing oxymetazoline, for example, offer fast and effective relief from nasal congestion. Unfortunately, oxymetazoline has undesired side-effects, one of which includes addiction if used beyond the recommended dosage period. Since many people who use nasal sprays remain symptomatic beyond the recommended dosage period, and despite warnings that the spray should not be used for more than three or four days, usage generally continues beyond the dosage period. Thus, a person using the spray in an effort to seek relief from their continued symptoms will subsequently become addicted.
Addiction or habitual overuse of nasal spray has a long and documented history in medical literature. "Rhinitis Medicamentosa" used in identifying the addiction or habitual S overuse is discussed in a 1994 article from the Department of Otorhinolaryngology at Soder Hospital, Karolinska Institute, Stockholm, Sweden, entitled "Overuse of Oxy-and Xylometazoline Nasal Sprays" by Peter Graf.
As described in the article, a compensatory vasodilation remains after the vasocontrictive effects of the drug have disappeared. The pathophysiology of this "rebound'' swelling caused by E O use of nasal spray is not known. After repeated use, a person will find that their sinuses become clogged due to this "rebound'' reaction to the spray. This leads a person to use the nasal spray repeatedly, causing increasing congestion. In time, the spray becomes increasingly less effective to the user. Alleviating this rebound swelling altogether requires that the use of the nasal spray be ceased.
One approach in treating the problem is immediate cessation, or stopping "cold turkey."
This type of withdrawal is very di~cult for people addicted to the habit, as it causes extreme discomfort. Other approaches in treating the problem include prescribing topical steroid nasal inhalers or oral systemic steroids which have a multitude of undesired side effects. Relief from congestion in many cases takes days or weeks and often sedatives are needed to help with the 0 resulting insomnia.
U.S. Patent Nos. 4,970,240 and 5,114,979 describe an aqueous topical nasal decongestant containing oxymetazoline or a salt thereof to which a fruity flavor is added to mask the aftertaste of the composition. No provision is made for assisting the user in withdrawing from addiction to these compositions.
S Methods and compositions for treating addiction to drugs, alcohol, and tobacco, such as those described in U.S. Patent Nos. 5,272,149; 5,219,858; 5,198,230;
4,496,545; 3,885,027;
4,582,705; 4,500,515; 4,596,825; 5,656.255; 5,688,804; and 5,594,030 are of possible general interest.
For those who are unable to stop using nasal sprays completely, there remains a need for 0 a device and method which is easy to use and effective for the withdrawal from addictive use of nasal sprays without the need for immediate cessation or steroids and accompanying side effects.
Briefly described, the invention comprises an apparatus and method for diluting nasal sprays containing addictive compounds which substantially reduces the concentration of the addictive compound in the spray and accordingly reduces the addiction or habitual overuse of these compounds.
The apparatus comprises a container holding a volume of nasal spray having at least one indicia at a pre-selected level on the container. The indicia is a mark, sign, or symbol signifying the level to which the nasal spray must be depleted prior to adding a diluent.
One example of an indicia is a horizontal line around the circumference of the container. The apparatus has a second indicia showing the initial volume of the spray in the container. The ievel to which the nasal spray is depleted is selected according to the needs of the user, since the severity of symptoms, mucosal swelling, and addiction to the spray is directly proportional to the frequency and dosage strength used. Generally, an indicia indicating 1 S% of the initial total volume is selected. When the user wishes to withdraw more rapidly from using the spray, a greater percentage of initial total volume will be removed.
Once the level is selected, the spray can either be administered or removed to the pre-selected level and discarded. Means are provided for depleting the nasal spray, such as an applicator nozzle or a removable top. The depleted volume of the nasal spray is replenished with a diluent, such as sodium chloride solution. Sodium chloride is employed as a diluting agent because it provides a soothing, moisturizing, and therapeutic effect. Diluent can be added to the nasal spray using an eye dropper, syringe, or other similar device.
The method comprises the successive dilution of the nasal spray using an apparatus having indicia at a pre-selected level. The nasal spray is depleted to the pre-selected level and replenished with a diluent, such as sodium chloride solution. Alternatively.
distilled water is employed as a diluent. Selecting a level to which the spray is depleted depends on the needs of the user, but generally the indicia is located at the level showing 15% from the total initial volume. The steps of the method are repeated until the concentration of the nasal spray is substantially reduced, and the user can withdraw from use of the spray without needless suffering. Optimally, the user can repeat the steps approximately thirty times, until the solution primarily consists of diluent.
These and other features of the invention will be more fully understood by reference to the following drawings.
FIG. I is a perspective view of the apparatus shown with two indicia.
FIG 2 is a perspective view of the apparatus shown with one indicia.
During the course of this description, like numbers will be used to identify like elements according to the different views that illustrate the invention.
The preferred embodiment of the invention 10 is illustrated in FIG. 1. The container 12 contains nasal spray 14 and is covered by a screw-off spray top 16. The container 12 is either a bottle for nasal solution or a plastic squeeze bottle for nasal spray. The top 16 is easily removable to allow access to the solution 14 at specific intervals when the diluent is added. The nasal spray 14 contains 0.05% oxymetazoline hydrochloride, but can contain other formulations containing addictive compounds known in the art.
S The container 12 has a first indicia 18 and a second indicia 20 around the periphery.
First indicia 18 is preferably located at the level showing I S% depletion of the total initial voltune of the spray 14. Second indicia 20 is located at the level showing the initial total volume of the spray 14. Initially, the person using the system will use the spray 14 at the normal dosage, and the level of fluid will fall below the second indicia 20. When the level of the nasal spray 14 reaches the first indicia 18, the user is prompted to add diluent. The user can then either add sodium chloride solution, or distilled water as diluent. Preferably, sodium chloride 0.065%
solution is employed. Diluent can be added by way of an eye dropper or syringe, being careful not to contaminate the nasal spray 14. Diluent is added until the level reaches the second indicia 20. The second indicia 20 aids the user when replenishing the depleted amount of nasal spray with a diluent. At this point, the concentration of the spray 14 is reduced by a factor of 15%.
This procedure is repeated approximately 30 times or until the concentration of the nasal spray 14 is substantially reduced.
Haw quickiy the solution needs dilution is determined completely by how often the person uses the medication and the amount used with each administration. This invention provides flexibility in allowing for comfortable and individualized withdrawal from addiction or habitual overuse to nasal spray. The gradual and comfortable withdrawal will help make the attempt to quit successful.
Optionally, a "fast track" approach is possible with the present invention.
Under this ! 5 approach, a person would not wait until the spray I4 is depleted to the first indicia 18. The container 12 can be emptied to the level of the first indicia 18, by either administration or disposal. The diluent can then be added on a daily basis, as opposed to an ''as needed" or consumption basis, and therefore, the attempt to quit is placed on a "fast track."
The reductions in concenuation provided by the invention are as follows:
DAY %STRENGTH
1 100.0 2 85.0 3 72.25 4 61.41 5 52.20 6 44.37 7 37.71 8 32.05 9 27.24 10 23.15 11 19.68 12 16.73 I3 14.22 1 ~ 14 12.09 10.28 16 8.74 I 7 7.43 18 6.3 2 '.0 19 5.37 4.56 21 3.88 22 3.30 23 2.81 5 24 2.39 2.03 26 1.73 27 1.47 28 1.25 0 29 1.06 0.90 This "fast track" approach provides a pre-determined 30-day withdrawal method.
Under the "fast track" method, a person should be able to completely stop using the system and be free of addiction at the end of thirty days.
FIG. 2 shows an alternate embodiment of the invention. One indicia 18 is shown on the container. Presumably, a user would know the initial level 22 of the spray prior to use. The indicia I8 indicates the Level at which the diluent should be added. The user can employ the procedures outlined above in the preferred embodiment when using the alternate embodiment of the invention.
While the invention has been described with reference to the preferred embodiment thereof, it will be appreciated by those of ordinary skill in the art that modifications can be made to the parts that comprise the invention without departing from the spirit and scope thereof.
CONTAINING ADDICTIVE COMPOUNDS
This invention relates to an apparatus and method for diluting nasal sprays containing addictive compounds which substantially reduces the strength of the spray.
Millions of people suffer from the symptoms of the common cold or other sinus-related problems, such as sinusitis and hay fever. Included among these symptoms is "rhinitis," a 0 medical term for blocked or clogged sinuses. Seeking relief from these symptoms, symptomatic persons use nasal decongestants which are available over-the-counter without a prescription. The most popular of these decongestants contain oxymetazoline or a pharmaceutically acceptable salt thereof. Other nasal preparations available over-the-counter contain compounds such as xylometazoline, naphazoline, phenylephrine and pharmaceutically acceptable salts thereof.
Nasal decongestants containing oxymetazoline, for example, offer fast and effective relief from nasal congestion. Unfortunately, oxymetazoline has undesired side-effects, one of which includes addiction if used beyond the recommended dosage period. Since many people who use nasal sprays remain symptomatic beyond the recommended dosage period, and despite warnings that the spray should not be used for more than three or four days, usage generally continues beyond the dosage period. Thus, a person using the spray in an effort to seek relief from their continued symptoms will subsequently become addicted.
Addiction or habitual overuse of nasal spray has a long and documented history in medical literature. "Rhinitis Medicamentosa" used in identifying the addiction or habitual S overuse is discussed in a 1994 article from the Department of Otorhinolaryngology at Soder Hospital, Karolinska Institute, Stockholm, Sweden, entitled "Overuse of Oxy-and Xylometazoline Nasal Sprays" by Peter Graf.
As described in the article, a compensatory vasodilation remains after the vasocontrictive effects of the drug have disappeared. The pathophysiology of this "rebound'' swelling caused by E O use of nasal spray is not known. After repeated use, a person will find that their sinuses become clogged due to this "rebound'' reaction to the spray. This leads a person to use the nasal spray repeatedly, causing increasing congestion. In time, the spray becomes increasingly less effective to the user. Alleviating this rebound swelling altogether requires that the use of the nasal spray be ceased.
One approach in treating the problem is immediate cessation, or stopping "cold turkey."
This type of withdrawal is very di~cult for people addicted to the habit, as it causes extreme discomfort. Other approaches in treating the problem include prescribing topical steroid nasal inhalers or oral systemic steroids which have a multitude of undesired side effects. Relief from congestion in many cases takes days or weeks and often sedatives are needed to help with the 0 resulting insomnia.
U.S. Patent Nos. 4,970,240 and 5,114,979 describe an aqueous topical nasal decongestant containing oxymetazoline or a salt thereof to which a fruity flavor is added to mask the aftertaste of the composition. No provision is made for assisting the user in withdrawing from addiction to these compositions.
S Methods and compositions for treating addiction to drugs, alcohol, and tobacco, such as those described in U.S. Patent Nos. 5,272,149; 5,219,858; 5,198,230;
4,496,545; 3,885,027;
4,582,705; 4,500,515; 4,596,825; 5,656.255; 5,688,804; and 5,594,030 are of possible general interest.
For those who are unable to stop using nasal sprays completely, there remains a need for 0 a device and method which is easy to use and effective for the withdrawal from addictive use of nasal sprays without the need for immediate cessation or steroids and accompanying side effects.
Briefly described, the invention comprises an apparatus and method for diluting nasal sprays containing addictive compounds which substantially reduces the concentration of the addictive compound in the spray and accordingly reduces the addiction or habitual overuse of these compounds.
The apparatus comprises a container holding a volume of nasal spray having at least one indicia at a pre-selected level on the container. The indicia is a mark, sign, or symbol signifying the level to which the nasal spray must be depleted prior to adding a diluent.
One example of an indicia is a horizontal line around the circumference of the container. The apparatus has a second indicia showing the initial volume of the spray in the container. The ievel to which the nasal spray is depleted is selected according to the needs of the user, since the severity of symptoms, mucosal swelling, and addiction to the spray is directly proportional to the frequency and dosage strength used. Generally, an indicia indicating 1 S% of the initial total volume is selected. When the user wishes to withdraw more rapidly from using the spray, a greater percentage of initial total volume will be removed.
Once the level is selected, the spray can either be administered or removed to the pre-selected level and discarded. Means are provided for depleting the nasal spray, such as an applicator nozzle or a removable top. The depleted volume of the nasal spray is replenished with a diluent, such as sodium chloride solution. Sodium chloride is employed as a diluting agent because it provides a soothing, moisturizing, and therapeutic effect. Diluent can be added to the nasal spray using an eye dropper, syringe, or other similar device.
The method comprises the successive dilution of the nasal spray using an apparatus having indicia at a pre-selected level. The nasal spray is depleted to the pre-selected level and replenished with a diluent, such as sodium chloride solution. Alternatively.
distilled water is employed as a diluent. Selecting a level to which the spray is depleted depends on the needs of the user, but generally the indicia is located at the level showing 15% from the total initial volume. The steps of the method are repeated until the concentration of the nasal spray is substantially reduced, and the user can withdraw from use of the spray without needless suffering. Optimally, the user can repeat the steps approximately thirty times, until the solution primarily consists of diluent.
These and other features of the invention will be more fully understood by reference to the following drawings.
FIG. I is a perspective view of the apparatus shown with two indicia.
FIG 2 is a perspective view of the apparatus shown with one indicia.
During the course of this description, like numbers will be used to identify like elements according to the different views that illustrate the invention.
The preferred embodiment of the invention 10 is illustrated in FIG. 1. The container 12 contains nasal spray 14 and is covered by a screw-off spray top 16. The container 12 is either a bottle for nasal solution or a plastic squeeze bottle for nasal spray. The top 16 is easily removable to allow access to the solution 14 at specific intervals when the diluent is added. The nasal spray 14 contains 0.05% oxymetazoline hydrochloride, but can contain other formulations containing addictive compounds known in the art.
S The container 12 has a first indicia 18 and a second indicia 20 around the periphery.
First indicia 18 is preferably located at the level showing I S% depletion of the total initial voltune of the spray 14. Second indicia 20 is located at the level showing the initial total volume of the spray 14. Initially, the person using the system will use the spray 14 at the normal dosage, and the level of fluid will fall below the second indicia 20. When the level of the nasal spray 14 reaches the first indicia 18, the user is prompted to add diluent. The user can then either add sodium chloride solution, or distilled water as diluent. Preferably, sodium chloride 0.065%
solution is employed. Diluent can be added by way of an eye dropper or syringe, being careful not to contaminate the nasal spray 14. Diluent is added until the level reaches the second indicia 20. The second indicia 20 aids the user when replenishing the depleted amount of nasal spray with a diluent. At this point, the concentration of the spray 14 is reduced by a factor of 15%.
This procedure is repeated approximately 30 times or until the concentration of the nasal spray 14 is substantially reduced.
Haw quickiy the solution needs dilution is determined completely by how often the person uses the medication and the amount used with each administration. This invention provides flexibility in allowing for comfortable and individualized withdrawal from addiction or habitual overuse to nasal spray. The gradual and comfortable withdrawal will help make the attempt to quit successful.
Optionally, a "fast track" approach is possible with the present invention.
Under this ! 5 approach, a person would not wait until the spray I4 is depleted to the first indicia 18. The container 12 can be emptied to the level of the first indicia 18, by either administration or disposal. The diluent can then be added on a daily basis, as opposed to an ''as needed" or consumption basis, and therefore, the attempt to quit is placed on a "fast track."
The reductions in concenuation provided by the invention are as follows:
DAY %STRENGTH
1 100.0 2 85.0 3 72.25 4 61.41 5 52.20 6 44.37 7 37.71 8 32.05 9 27.24 10 23.15 11 19.68 12 16.73 I3 14.22 1 ~ 14 12.09 10.28 16 8.74 I 7 7.43 18 6.3 2 '.0 19 5.37 4.56 21 3.88 22 3.30 23 2.81 5 24 2.39 2.03 26 1.73 27 1.47 28 1.25 0 29 1.06 0.90 This "fast track" approach provides a pre-determined 30-day withdrawal method.
Under the "fast track" method, a person should be able to completely stop using the system and be free of addiction at the end of thirty days.
FIG. 2 shows an alternate embodiment of the invention. One indicia 18 is shown on the container. Presumably, a user would know the initial level 22 of the spray prior to use. The indicia I8 indicates the Level at which the diluent should be added. The user can employ the procedures outlined above in the preferred embodiment when using the alternate embodiment of the invention.
While the invention has been described with reference to the preferred embodiment thereof, it will be appreciated by those of ordinary skill in the art that modifications can be made to the parts that comprise the invention without departing from the spirit and scope thereof.
Claims (20)
1. ~A method for diluting a nasal spray containing addictive compounds, comprising the steps of:
providing a container for holding an initial volume of nasal spray with indicia at a pre-selected level;
depleting an amount of spray to the pre-selected level;
replenishing the depleted amount with diluent; and repeating the steps of depleting and replenishing until the strength of said spray is substantially reduced.
providing a container for holding an initial volume of nasal spray with indicia at a pre-selected level;
depleting an amount of spray to the pre-selected level;
replenishing the depleted amount with diluent; and repeating the steps of depleting and replenishing until the strength of said spray is substantially reduced.
2. ~The method according to claim 1. wherein said indicia comprises a first horizontal line around the circumference of said container.
3. ~The method according to claim 2, wherein said indicia further comprises a second horizontal line around the circumference of said container indicating initial volume.
4. ~The method according to claim 3, wherein said diluent comprises sodium chloride solution.
5. ~The method according to claim 3, wherein said diluent comprises distilled water.
6. ~The method according to claim 4, wherein said addictive compound comprises oxymetazoline or a pharmaceutically acceptable salt thereof.
7. ~The method according to claim 5, wherein said steps of depleting and replenishing are repeated approximately 30 times.
8. ~A method for gradually diluting a nasal spray containing addictive compounds, comprising the steps of:
providing a bottle for containing nasal spray with means for indicating a level where a selective amount of the initial volume of spray in said bottle is to be depleted;
depleting the volume of said spray by said selective amount;
adding diluent to said bottle until the initial volume is reached; and repeating the steps of depleting and adding until the concentration of said spray is substantially reduced.
providing a bottle for containing nasal spray with means for indicating a level where a selective amount of the initial volume of spray in said bottle is to be depleted;
depleting the volume of said spray by said selective amount;
adding diluent to said bottle until the initial volume is reached; and repeating the steps of depleting and adding until the concentration of said spray is substantially reduced.
9. ~The method according to claim 8, wherein said means for indicating comprises a first horizontal line around the circumference of said bottle.
10. ~The method according to claim 9, wherein said means for indicating further comprises a second horizontal line around the circumference of said bottle indicating initial volume.
11. ~The method according to claim 10, wherein said selective amount is approximately 15%.
12. ~The method according to claim 11, wherein said diluent comprises sodium chloride solution.
13. ~The method according to claim 11, wherein said diluent comprises distilled water.
14. ~The method according to claim 12, wherein said addictive compound comprises oxymetazoline or a pharmaceutically acceptable salt thereof.
15. ~The method according to claim 14, wherein the steps of depleting and adding are repeated approximately 30 times.
16. ~An apparatus capable of diluting a nasal spray containing addictive compounds, comprising:
a container with a volume of nasal spray at an initial level;~
at least one indicia at a pre-selected level on said container;
means for depleting said nasal spray; and means for replenishing said depleted nasal spray with a diluent. wherein when said spray is depleted to said pre-selected level. said diluent is added to replenish the volume to said initial level of said spray.
a container with a volume of nasal spray at an initial level;~
at least one indicia at a pre-selected level on said container;
means for depleting said nasal spray; and means for replenishing said depleted nasal spray with a diluent. wherein when said spray is depleted to said pre-selected level. said diluent is added to replenish the volume to said initial level of said spray.
17. ~The apparatus of claim 16, wherein said at least one indicia is located at the level of 85% of the initial volume of spray.
18. ~The apparatus of claim 17, further comprising a second indicia on said container showing the initial level of said spray in said container.
19. ~The apparatus of claim 18, wherein said diluent is sodium chloride solution.
20. ~The apparatus of claim 19, wherein said container has a screw-off top for ease in adding diluent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/033,252 | 1998-03-02 | ||
| US09/033,252 US5988870A (en) | 1998-03-02 | 1998-03-02 | Apparatus and method for diluting nasal sprays containing addictive compounds |
| PCT/US1999/004446 WO1999044587A1 (en) | 1998-03-02 | 1999-03-01 | Apparatus and method for diluting nasal sprays containing addictive compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2312744A1 CA2312744A1 (en) | 1999-09-10 |
| CA2312744C true CA2312744C (en) | 2007-03-27 |
Family
ID=21869364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002312744A Expired - Fee Related CA2312744C (en) | 1998-03-02 | 1999-03-01 | Apparatus and method for diluting nasal sprays containing addictive compounds |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5988870A (en) |
| EP (1) | EP1023046A4 (en) |
| AU (1) | AU2798899A (en) |
| CA (1) | CA2312744C (en) |
| WO (1) | WO1999044587A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6712803B1 (en) * | 1999-08-11 | 2004-03-30 | Howard Paritsky | Drug dispensing system |
| FR2832329B1 (en) * | 2001-11-20 | 2004-11-19 | Valois Sa | SIDE OPERATION SPRAYING DEVICE |
| US7714011B2 (en) * | 2002-09-13 | 2010-05-11 | Zicam, Llc | Compositions to reduce congestion and methods for application thereof to the nasal membrane |
| US20040235807A1 (en) * | 2003-05-21 | 2004-11-25 | Weinrich Karl P. | Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea |
| CH702425A1 (en) | 2009-12-28 | 2011-06-30 | Innostarter Ag | Container for receiving and Abgae a liquid and / or dissolved in particular pharmaceutical active substance |
| DE102010042360A1 (en) | 2010-10-12 | 2012-04-12 | Andreas Charap | Nasal spray bottle, useful for dilution of drug to be administered, and for preventing or treating rhinitis medicamentosa, preferably withdrawal rhinitis medicamentosa, comprises a spray nozzle and a two chamber system |
| US20160144083A1 (en) * | 2014-11-24 | 2016-05-26 | Dai Vinh | Nasal aspirator device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US53790A (en) * | 1866-04-10 | Improvement in apparatus for administering medicines | ||
| US2564400A (en) * | 1949-10-29 | 1951-08-14 | Sharp & Dohme Inc | Atomizer |
| US3140052A (en) * | 1963-01-21 | 1964-07-07 | Richardson Merrell Inc | Spray nozzle comprising a base member and a cap |
| US4564129A (en) * | 1983-01-27 | 1986-01-14 | Hoechst-Roussel Pharmaceuticals Inc. | Dosage dispensing unit |
| US5272149A (en) * | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
| JPH07506379A (en) * | 1992-08-04 | 1995-07-13 | ファイザー・インコーポレーテッド | 3-benzylamino-2-phenyl-piperidine as substance P receptor antagonist |
-
1998
- 1998-03-02 US US09/033,252 patent/US5988870A/en not_active Expired - Lifetime
-
1999
- 1999-03-01 AU AU27988/99A patent/AU2798899A/en not_active Abandoned
- 1999-03-01 CA CA002312744A patent/CA2312744C/en not_active Expired - Fee Related
- 1999-03-01 WO PCT/US1999/004446 patent/WO1999044587A1/en active Application Filing
- 1999-03-01 EP EP99908593A patent/EP1023046A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2312744A1 (en) | 1999-09-10 |
| EP1023046A1 (en) | 2000-08-02 |
| US5988870A (en) | 1999-11-23 |
| EP1023046A4 (en) | 2007-12-26 |
| AU2798899A (en) | 1999-09-20 |
| WO1999044587A1 (en) | 1999-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4546699B2 (en) | Spray equipment | |
| JP5632284B2 (en) | Compositions and methods for sedation and analgesia during treatment using oral transmucosal dosage forms | |
| US5941241A (en) | Method and device for organizing and coordinating the combined use of topical aerosols for the treatment of respiratory disorders | |
| US20030077300A1 (en) | System and method for intranasal administration of opioids | |
| US5806723A (en) | Device for lavaging | |
| US20060147386A1 (en) | System and method for intranasal administration of lorazepam | |
| WO2004024226A1 (en) | Device for delivering a viscous medical solution to the nasal membrane and method for using same | |
| WO2005020906A2 (en) | Intranasal opioid compositions | |
| US20190262263A1 (en) | Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions | |
| WO1992005781A1 (en) | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form | |
| CA2312744C (en) | Apparatus and method for diluting nasal sprays containing addictive compounds | |
| US7714011B2 (en) | Compositions to reduce congestion and methods for application thereof to the nasal membrane | |
| US6294178B1 (en) | Method and device for coordinating topical and oral sinusitis treatments | |
| JP2003176227A (en) | Pharmaceutical composition, method for alleviating tobacco-smoking withdrawal symptom in patient refraining from smoking, and kit for alleviating tobacco- smoking withdrawal symptom in patient | |
| WO2000018379A2 (en) | Pharmaceutical preparation for use in a method to abate the use of tobacco by humans | |
| US6712803B1 (en) | Drug dispensing system | |
| US20090221987A1 (en) | Portable sinus and throat cleansing system and method | |
| WO2021158736A1 (en) | Method, apparatus and kit for treating chronic and long-term nasal congestion | |
| Oswald | Assessment of insomnia. | |
| US6932978B2 (en) | Double-headed, closed-mouth cough suppressant and cold relief device | |
| Winfield et al. | Routes of administration and dosage forms | |
| EP4304595A1 (en) | Naloxone for use in the treatment of an opioid overdose administered by a drug delivery device | |
| WO2022192652A1 (en) | Naloxone for use in the treatment of a opioid overdose administerd by a drug delivery device | |
| AU2006202584B2 (en) | An albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| WO2004064667A1 (en) | Unit dose delivery system for dental sensitivity product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |